If your bloodwork shows elevated LDL cholesterol levels, you can take steps to reduce it. Eat a healthy diet low in saturated ...

Atherogenic lipoprotein particles can vary considerably in their cholesterol content, but each particle contains only one molecule of apoB-100 (or simply apoB). As a result, serum concentration of ...

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...

Many randomized trials have established that the risk reduction for cardiovascular (CV) disease is proportional to the absolute reduction of low-density-lipoprotein cholesterol (LDL-C). Nevertheless, ...

Findings showed the trial met the primary endpoint, with enlicitide demonstrating a statistically significantly meaningful reduction in LDL-C compared with placebo. Topline data were announced from a ...

A greater reduction LDL-C was seen for combo therapy; reductions also seen in all-cause mortality, major adverse CV events, stroke incidence. HealthDay News — Combination lipid-lowering therapy (LLT) ...

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant ...

Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today released a note authored by inventor and ...

LDL-C is considered to be the major lipid risk factor and the main target of lipid-lowering therapy. Nevertheless, as all potentially atherogenic lipoprotein particles contain only one molecule of ...